ARS Pharmaceuticals (SPRY) News Today

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) is facing a concentrated wave of securities-fraud lawsuit notices, creating a legal and reputational overhang for investors. The filings allege that the company misrepresented the timing of expanded CVS Caremark coverage for its neffy nasal epinephrine product, followed by a reported single-day 23.9% share decline. The repeated law-firm announcements are the primary stock-related news in the latest coverage and may weigh on sentiment, even as the shares have recently moved higher.

• Positive Sentiment: No new operational, regulatory, or financial catalyst was reported that would directly support the stock. However, the current announcements are largely reminders about investor rights rather than new allegations or a new enforcement action. SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals Securities Fraud Lawsuit
• Neutral Sentiment: Several firms, including SBS Law, Rosen Law Firm, Faruqi & Faruqi, Grabar Law Office, Bronstein Gewirtz & Grossman, Levi & Korsinsky, and Kaplan Fox, are soliciting investors who purchased SPRY shares between March 9 and June 24, 2026. The notices concern participation in an existing federal securities class action and the selection of a lead plaintiff. SBS Law SPRY Investor Notice
• Negative Sentiment: The lawsuit allegations could increase legal costs, distract management, and expose ARS Pharmaceuticals to potential damages or settlement payments. The lead-plaintiff deadline is October 5, 2026, keeping the issue active for investors in the near term. Faruqi SPRY Equity Action Reminder